3 Houston health care innovators to know this week

who's who

This week's roundup of Houston innovators includes Tom Luby of TMC Innovation, Ayse McCracken of Ignite Health, and Chris DuPont of Galen Data. Photos courtesy

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes three innovators across health care innovation.

Tom Luby, director of TMC Innovation

Texas Medical Center Innovation won a Prix Galien Award, which has been described as being comparable to the Nobel Prize for the life science community. Photo by Natalie Harms/InnovationMap

Last month, a global organization honored innovation leaders in life sciences, and the Texas Medical Center was among the recipients of the prestigious awards program.

The 18th annual Prix Galien Awards Gala awarded TMC Innovation with the win in the "Incubators, Accelerators and Equity" category. The Galien Foundation created the awards program in 1970 in honor of Galien, the father of medical science and modern pharmacology. Alongside TMC, the other winners represented biotech, digital health, startups, and more.

"We are super proud of this distinction," Tom Luby, director of TMC Innovation says at Envision 2024 last month, crediting the TMCi team and TMC leadership for the award. "We lean on a lot of advisers and experts — people who volunteer their time to work with startups. Without (them), we would not have been successful." Continue reading.

Ayse McCracken, founder of Ignite Health

A Houston organization that accelerates and supports female founders leading innovative health tech startups has concluded its 2024 program with the announcement of this year's top companies.

Ignite Health, an accelerator founded in 2017 by longtime Houston health care professional Ayse McCracken, named its 2024 winners at its annual Fire Pitch Competition in Houston last month. The companies pitched health tech solutions across lung health, renal therapy, breastfeeding tech, and more.

"This year’s competition was a culmination of passion, innovation, and hard work from the top startups in our 2024 Accelerator Program," reads a LinkedIn post from Ignite. "These trailblazing founders earned their spot on the stage by demonstrating exceptional leadership and the potential to revolutionize the healthcare industry with their solutions and devices." Continue reading.

Chris DuPont, co-founder and CEO of Galen Data

Houston-based Galen Data, a provider of cloud-based connectivity software for medical devices, has been acquired. Photo via LinkedIn

Houston-based Galen Data, a provider of cloud-based connectivity software for medical devices, has been acquired by health care-focused asset manager Lauxera Capital Partners. Financial terms weren’t disclosed.

Lauxera, based in France, says the Galen Data acquisition complements its 2022 purchase of Germany-based Matrix Requirements, a provider of software for medical device R&D and quality control teams.

Chris DuPont, co-founder and CEO of Galen Data, says the Lauxera deal “empowers us to take our business to the next level and better serve our clients while pushing forward the innovation that’s at the core of everything we do.” Continue reading.

Texas Medical Center Innovation won a Prix Galien Award, which has been described as being comparable to the Nobel Prize for the life science community. Photo by Natalie Harms/InnovationMap

Houston's Texas Medical Center wins prestigious global award recognizing leaders in life science innovation

new bling

Last month, a global organization honored innovation leaders in life sciences, and the Texas Medical Center was among the recipients of the prestigious awards program.

The 18th annual Prix Galien Awards Gala awarded TMC Innovation with the win in the "Incubators, Accelerators and Equity" category. The Galien Foundation created the awards program in 1970 in honor of Galien, the father of medical science and modern pharmacology. Alongside TMC, the other winners represented biotech, digital health, startups, and more.

"We are super proud of this distinction," Tom Luby, director of TMC Innovation says at Envision 2024 last month, crediting the TMCi team and TMC leadership for the award. "We lean on a lot of advisers and experts — people who volunteer their time to work with startups. Without (them), we would not have been successful."

Luby explains that a Prix Galien Award holds a Nobel Prize level of significance for the community.

TMCi was named a finalist in August, and competed against programs from Cedars-Sinai, Mayo Foundation for Medical Education and Research, TechConnect, and more.

"The Awards Committee is honored to witness the exceptional dedication and creativity of our nominees as they turn visionary ideas into transformative solutions for patients worldwide," says Michael Rosenblatt, chair of the Prix Galien USA Awards Committee, in a news release. "Their unwavering commitment to advancing patient care is truly commendable, and we are honored to celebrate their outstanding contributions to global health."

The award is displayed at TMC Innovation's office, located in the medical center at 2450 Holcombe Blvd.

At its annual Activation Festival, the Ion hosted a conversation about the relationship between corporates and startups. Photo courtesy of Shannon O'Hara/the Ion

Overheard: What Houston corporates are looking for from startups

eavesdropping at the ion

Hundreds of innovators from Houston and beyond flocked to the Ion's annual Activation Festival, and one of the topics discussed at the series of programming was the relationship between corporates and startups.

One of Houston's points of pride is having the third most Fortune 500 companies headquartered here, but how can the city's innovation ecosystem take advantage of that market? And, on the other side of it, how can corporates make the most of Houston innovators?

At a panel on May 17 entitled "Corporate-Startup Partnerships: How to Build Them, Sustain Them, and How They’re Key to Fast-Tracking Innovation and Growth," three corporate leaders explained how they navigate relationships with startups and how cultivating these opportunities is key to the future of business.

Here are a few of the discussion's highlights.

“Investing in the startup community generally, you’re never going to have a line of sight of where that value is going to come back. You can expect it — I’m not saying it’s altruism, it just comes back in forms that you might not appreciate.”

— Scott Gale, executive director of Halliburton Labs says, explaining that corporate contribution doesn't just have to be financial.

“Ask for advice, don’t ask for money. Show up. Be curious. If you think a corporate is the right potential customer for you, spend the time to try to understand what the people are, who the champions are, what motivates them, and what they need to do to be successful.” 

— Tom Luby, director of TMC Innovation says, noting that it's tried-and-true advice, but still important to remember.

“The person who takes the most risk is the lead adopter — the lead user. That person puts their assets and their name on the line.”

— Nazeer Bhore, global manager, tech scouting, innovation and ventures at ExxonMobil Technology and Engineering, says. “What we bring to the table for startups is all the resources we have — technical resources, assets, use cases, testing facilities, and, of course, funding. Irrespective of what stage you’re in, or how many adjacencies you are, we’re always happy to engage with you," he explains. "The key is for us is to be a lead user.”

“The opportunity for us is to be generalists across a lot of different spaces and then work with our specialists to take a deeper dive. We listen to the market and try to find things our corporate partners or entrepreneurs are interested in and then surround them with the type of things they need to be successful. In many case, talent and expertise are top of that list.”

— Luby says, explaining the nature of the TMC's various programs, from creating startup tech directly and supporting them through their accelerators and even seeding them through the TMC Venture Fund.

“What startups bring is a lot of different ideas — but startups are temporary organizations that’s looking for a scalable and repeatable business model. And we’re not just interested in just the technology, but the business model.”

— Bhore says about what ExxonMobil looks for.

“The flywheel is spinning here in the city of Houston. The next five years are going to be incredibly exciting.”

— Gale says, explaining how much has changed in the past few years in Houston's innovation ecosystem.

These three health tech startups are moving on in TMCi's accelerator program. Photo courtesy of TMC

TMC names 3 startups to Houston health tech accelerator

onboarding tech

Thee Texas Medical Center named three companies to its accelerator program. The health tech startups will join the program and make key connections to grow their technology and business.

Texas Medical Center Innovation announced this year's cohort for the TMC Innovation Accelerator for HealthTech. The companies attended TMCi's boot camp earlier this year before being named to the cohort.

“It is always exciting to introduce a new group of talented entrepreneurs into our community,” says Tom Luby, director of TMC Innovation, in a news release. “Each with their own goals, and at their individual stage, we’ll work closely together to help them learn, grow and navigate this rich clinical landscape. We are honored to be the bridge between these innovators and the world’s largest medical city.”

The selected startups include Oxford, United Kingdom-based CardMedic, which joins the program by way of TMC's UK BioBridge, an international partnership established to bring cutting-edge health tech startups to the United States by way of Houston. The company's technology is a digital "One Stop Communication Shop" — an extensive library of pre-written scripts that help staff and patients communicate across any barrier, including language, deafness, cognitive impairment, or disability.

“The opportunity to connect with Texas Medical Center member institutions, understand their problem domain, and in what ways that may differ from the United Kingdom is invaluable. We are really excited about learning from the expert team of strategic advisors at the TMCi Accelerator about areas we needed to focus on to grow our company in the United States,” says Rachael Grimaldi, co-founder and CEO of CardMedic.

Chicago-based CareAdvisors, which helps hospitals and clinical social workers connect patients to the best resources and benefits to address social care needs, also joins the TMCi accelerator. The company's technology, the Social Care Automation tool, enables hospitals to generate revenue from preventive health programs and helps health plans reduce overutilization by putting the focus on preventive care.

Roboligent, based in Austin, designs and manufactures robotic and automated physical therapy exercises for patients with upper and lowers limb musculoskeletal issues. This robotic-assisted rehab help promotes recovery while increasing rehab centers’ operational efficiency.

“Introducing a new and innovative product, especially in the medical device field, is a thorough and collaborative effort,” says Bongsu Kim, founder and CEO of Roboligent, in a news release. “TMC’s HealthTech Accelerator is the perfect place to make connections with experts and stakeholders to help guide us in reaching our next milestone.”

The Texas Medical Center's Innovation Institute named 15 Texas companies to its new cancer-focused accelerator program. Photo courtesy of TMCx

TMC cancer therapeutic accelerator names inaugural cohort

cancer innovation

The Texas Medical Center named 15 groundbreaking researchers and companies to its inaugural class of the Accelerator for Cancer Therapeutics on Thursday. All hail from the Lone Star State.

The ACT program is the only accelerator focused on cancer treatment at the earliest stages of commercialization, thanks to a $5 million grant from the Cancer Prevention and Research Institute of Texas awarded to the TMC in the fall of 2019.

The nine-month program kicked-off at the end of January and will be run by TMC Innovation, according to a release from the TMC. It aims to provide the class with resources to help their oncology biotech projects reach new milestones, including even commercialization.

The inaugural cohort is made up of companies and researchers exploring immunotherapy, cell therapy, targeted therapy, cancer pain, and drug platforms. The group is split about evenly between companies and academic researchers. The group of Texans includes:

  • Raptamer Discovery Group
  • IDA Therapeutics
  • Elbrus Therapeutics
  • Parthenon Therapeutics
  • Lokesh Battula
  • Aumeta
  • Autoimmunity Biologic Solutions
  • Max Mamonkin
  • Qing Yi
  • Astero Alta
  • TEZCAT Laboratories
  • Anil Sood
  • Coactigon
  • Xiadong Cheng
  • IonTx

At the end of the nine months, the class will present an integrated strategic plan and at least one grant submission. They will also have the opportunity to pitch investors and corporations.

The class will also gain support in grant writing, chemistry, and funding opportunities, as well as mentorship.

"As the past year has shown, the pace of scientific discovery can be blistering," says Tom Luby, director of TMC Innovation. "At the same time, successfully translating research into effective therapies available to patients requires a mix of business, technical and regulatory skills that may not typically be available to researchers.

"By linking the participants with mentors who can both advance their scientific work and support the technical needs, we expect this first class of ACT participants will make a meaningful difference for cancer patients in Texas and beyond."

TMCx, which is also run by TMC Innovation, recently announced seven health tech companies that were selected to its 2021 class of its health tech accelerator.

Broader in scope that the ACT accelerator, the TMCx startups focus on an array of subject matters from heart health to artificial intelligence to extremity rehabilitation.

Unlike past awards programs hosted by Ignite Healthcare Network, the Ignite Madness winners accepted their awards via video call. Photo courtesy of Ignite

Houston female-focused health tech pitch competition names big winners

winner, winner

From the comfort of their own homes, several female entrepreneurs accepted investment and pitch prizes at the finals of an inaugural awards program created by a Houston-based, woman-focused health organization.

Ahead of the Ignite Madness finals on Thursday, October 29, Houston-based Ignite Healthcare Network named nine finalists that then pitched for three investment prizes. The finalists included:

  • Eden Prairie, Minnesota-based Abilitech Medical — medical device company that creates assistive devices to aid those with upper-limb neuromuscular conditions or injuries.
  • New Orleans, Louisiana-based Chosen Diagnostics — a biotech company focusing on custom treatment. First, Chosen is focused on creating two novel biomarker diagnostic kits — one for gastrointestinal disease in premature infants.
  • San Francisco, California-based Ejenta — which uses NASA tech and artificial intelligence to enhance connected care.
  • Highland, Maryland-based Emergency Medical Innovation — a company focused on emergency medicine like Bleed Freeze, a novel device for more efficiently treating nosebleeds.
  • Columbia, Missouri-based Healium — an app to quickly reduce burnout, self-manage anxiety, and stress.
  • Farmington, Connecticut-based Nest Collaborative — digital lactation solutions and support.
  • Palo Alto, California-based Nyquist Data — a smart search engine to enable medical device companies to get FDA approvals faster.
  • New Orleans-Louisiana based Obatala Sciences — a biotech startup working with research institutions across the globe to advance tissue engineering and regenerative medicine.
  • Perth, Australia-based OncoRes — a company that's developing a technology to provide surgeons with real-time assessment of tissue microstructure.
The inaugural event that mixed health care and basketball — two vastly different industries with strong connections to women — attracted support from partners and sponsors, such as Intel, Accenture, Morgan Lewis, Houston Methodist, Johnson & Johnson Innovation, and more, according to Ayse McCracken, founder and board chair of Ignite.

"Our partners and sponsors are an integral part of our organization" says McCracken. "Without each and every one of them, the networks, resources, and commitment to advancing women leaders, we would not have grown so rapidly in just four years and our IGNITE Madness event would not enjoy this vibrant ecosystem that now surrounds female entrepreneurs."

First up in selecting their winner for their investment was Texas Halo Fund. Chosen Diagnostics took home the $50,000 investment.

"While we were impressed by everyone who pitched tonight, one company stood out to us," says Kyra Doolan, managing partner. "[Chosen Diagnostics] exemplifies what we are looking for: an innovative solution, a strong CEO, and a real addressable market."

The second monetary award was presented by Tom Luby, director of TMC Innovation. The award was an $100,000 investment from the TMC Venture Fund, as well as admission to TMCx. The recipient of the investment was OncoRes.

"We are absolutely blown away," says Katharine Giles, founder of Onco. "We've already got a great link to Texas and looking forward to more."

The largest monetary award that was on the table was presented by Wavemaker Three-Sixty Health, a leading Southern-California based, early stage venture capital firm, for $150,000. However, at the time of the announcement, Managing Partner Jay Goss decided to award four startups an undisclosed amount of investment. Goss says he and his team will meet with each company to establish an investment.
The companies that were recognized by Wavemaker were: Healium, Ejenta, Emergency Medical Innovation, and Nest Collaborative.
Lastly, Ignite itself had $27,500 cash awards to give out to the pitch competition winners. The funds will be distributed between the winners. OncoRes took first place, Abilitech came in second place, and Obatala Sciences took third place.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Axiom Space taps solar array developer for first space station module

space contract

Houston-based Axiom Space is making progress on developing its commercial space station.

The company awarded Florida-based Redwire Corporation a contract to develop and deliver roll-out solar array (ROSA) wings to power the Axiom Payload Power Thermal Module (AxPPTM), which will be the first module for the new space station.

AxPPTM will initially attach to the International Space Station. AxPPTM will later separate from the ISS and rendezvous with Axiom’s Habitat 1 (AxH1) on orbit. Eventually, an airlock, Habitat 2 (AxH2) and finally the Research and Manufacturing Facility (AxRMF) will be added to the first two Axiom modules.

AxPPTM is anticipated to launch toward the end of 2027. The two-module station (AxPPTM and AxH1) is expected to be operational as a free-flying station by 2028, and the full four-module station around 2030.

The modules will be integrated and assembled at Axiom Space’s Assembly and Integration facility, making them the first human-rated spacecraft built in Houston.

Redwire’s ROSA technology was originally developed for the ISS, according to Space News. It has yielded a 100 percent success rate on on-orbit performance. The technology has also been used on NASA’s Double Asteroid Redirection Test mission, the Maxar-built Power and Propulsion Element for the Artemis Lunar Gateway and Thales Alenia Space’s Space Inspire satellites.

“As a market leader for space power solutions, Redwire is proud to be selected as a strategic supplier to deliver ROSAs for Axiom Space’s first space station module,” Mike Gold, Redwire president of civil and international space, said in a news release. “As NASA and industry take the next steps to build out commercial space stations to maintain U.S. leadership in low-Earth orbit, Redwire continues to be the partner of choice, enabling critical capabilities to ensure on-orbit success.”

Greentown Houston to add new AI lab for energy startups

AI partnership

Greentown Labs has partnered with Shoreless to launch an AI lab within its Houston climatetech incubator.

"Climatetech and energy startups are transforming industries, and AI is a critical tool in that journey," Lawson Gow, Greentown's Head of Houston, said in a news release. "We're excited to bring this new offering to our entrepreneurs and corporate partners to enhance the way they think about reducing costs and emissions across the value chain."

Shoreless, a Houston-based company that enables AI adoption for enterprise systems, will support startups developing solutions for supply-chain optimization and decarbonization. They will offer Greentown members climate sprint sessions that will deliver AI-driven insights to assist companies in reducing Scope 3 emissions, driving new revenue streams and lowering expenses. Additionally, the lab will help companies test their ideas before attempting to scale them globally.

"The future of climatetech is intertwined with the future of AI," Ken Myers, Founder and CEO of Shoreless, said in a news release. "By launching this AI lab with Greentown Labs, we are creating a collaborative ecosystem where innovation can flourish. Our agentic AI is designed to help companies make a real difference, and we are excited to see the groundbreaking solutions that will emerge from this partnership."

Greentown and Shoreless will collaborate on workshops that address industry needs for technical teams, and Shoreless will also work to provide engagement opportunities and tailored workshops for Greentown’s startups and residents. Interested companies can inquire here.

Recently, Greentown Labs also partnered with Los Angeles-based software development firm Nominal to launch the new Industrial Center of Excellence at Greentown's Houston incubator. It also announced a partnership with Houston-based EnergyTech Nexus, which will also open an investor lounge on-site last month. Read more here.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston medical institutions launch $6M kidney research incubator

NIH funding

Institutions within Houston’s Texas Medical Center have launched the Houston Area Incubator for Kidney, Urologic and Hematologic Research Training (HAI-KUH) program. The incubator will be backed by $6.25 million over five years from the National Institutes of Health and aims to create a training pipeline for researchers.

HAI-KUH will include 58 investigators from Baylor College of Medicine, Texas Children’s Hospital, the University of Texas Health Science Center at Houston, University of Houston, Houston Methodist Research Institute, MD Anderson Cancer Center, Rice University and Texas A&M University Institute of Biosciences and Technology. The program will fund six predoctoral students and six postdoctoral associates. Trainees will receive support in scientific research, professional development and networking.

According to the organizations, Houston has a high burden of kidney diseases, hypertension, sickle cell disease and other nonmalignant hematologic conditions. HAI-KUH will work to improve the health of patients by building a strong scientific workforce that leverages the team's biomedical research resources to develop research skills of students and trainees and prepare them for sustained and impactful careers. The funding comes through the National Institute of Diabetes and Digestive and Kidney Diseases.

The principal investigators of the project include Dr. Alison Bertuch, professor of pediatric oncology and molecular and human genetics at BCM; Peter Doris, professor and director of the Institute of Molecular Medicine Center for Human Genetics at UT Health; and Margaret Goodell, professor and chair of the Department of Molecular and Cellular Biology at Baylor.

“This new award provides unique collaborative training experiences that extend beyond the outstanding kidney, urology, and hematology research going on in the Texas Medical Center,” Doris said in a news release. “In conceiving this award, the National Institute of Diabetes and Digestive and Kidney Diseases envisioned trainee development across the full spectrum of skills required for professional success.”

Jeffrey Rimer, a professor of Chemical Engineering, is a core investigator on the project and program director at UH. Rimer is known for his breakthroughs in using innovative methods in control crystals to help treat malaria and kidney stones. Other co-investigators include Dr. Wolfgang Winkelmeyer (Baylor), Oleh Pochynyuk (UTHealth), Dr. Rose Khavari (Houston Methodist) and Pamela Wenzel (UT Health).

“This new NIH-sponsored training program will enable us to recruit talented students and postdocs to work on these challenging areas of research,” Rimer added in a release.

View All Listings